EGFR and non-small cell lung carcinoma: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), typified by osimertinib, yield substantial efficacy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations.